A rare case of incidentally diagnosed pulmonary inflammatory myofibroblastic tumour with dramatic response to crizotinib in a postpartum woman

Authors

• Jojo Yorke Department of Internal Medicine, Division of Pulmonary/Critical Care, James H. Quillen College of Medicine, East Tennessee State University, Johnson City, USA
• Krupa Solanki Department of Internal Medicine, Division of Pulmonary/Critical Care, James H. Quillen College of Medicine, East Tennessee State University, Johnson City, USA
• Vaishnavi Theegala Department of Internal Medicine, Division of Pulmonary/Critical Care, James H. Quillen College of Medicine, East Tennessee State University, Johnson City, USA
• Alok Kumar Sinha Department of Pathology, James H. Quillen College of Medicine, East Tennessee State University, Johnson City, USA
• Don E Asberry Department of Pathology, Highlands Pathology, Bristol, USA
• Adel El Abbassi Bristol Regional Medical Center, Bristol, USA

jojoyorke@gmail.com

Keywords

Abstract

Introduction: Inflammatory myofibroblastic tumours are rare neoplasms which most commonly affect children and young adults. With an intermediate malignant potential, they are typically detected in the abdomen, lung, mediastinum, head and neck, gastrointestinal tract, and genitourinary tract.

Case description: We describe the case of a 33-year-old postpartum woman incidentally diagnosed with a pulmonary inflammatory myofibroblastic tumour following complaints of poorly controlled hypertension a week after caesarean section. She was ALK-negative and received an ALK inhibitor with complete resolution of the lesion. A ROS1–TFG fusion confirmed the diagnosis of an inflammatory myofibroblastic tumour after CT-guided fine needle aspiration.

Discussion: This case highlights an uncommon presentation posing a diagnostic and therapeutic challenge and the potential treatment option of crizotinib.

References